Cannabis for PMS & endometriosis

TL;DR

• Endometriosis affects ~10 % of women — cannabis as a complementary approach.
• Sinclair (2018) survey of >200 women: 96 % reported symptom relief.
• CBD:THC 1:1 (2.5–5 mg oral each) often effective for chronic pelvic pain.
• Does not replace standard therapy (NSAIDs, hormones, surgery).

Application protocols

• PMS headaches: 15–20 mg CBD oil sublingual, twice daily days −5 to 0.
• Menstrual cramps: THC vaginal suppositories (where legal) or oral CBD oil.
• Endometriosis: steady CBD base dose (25–50 mg/day) + THC micro (2.5 mg) during flares.
• Always discuss with a gynecologist — interaction with hormonal contraception possible.

Physiological mechanisms in the female pelvis

The endocannabinoid system plays a fundamental role in regulating physiological processes in the female reproductive system. CB1 and CB2 receptors have been detected in the endometrium, myometrium, and ovaries. These receptors interact directly with endogenous cannabinoids to modulate processes such as tissue regeneration and pain perception. In conditions such as endometriosis, researchers suspect a dysregulation of this system, which can lead to increased pain sensitivity and inflammatory processes in the pelvic area. The targeted administration of plant-derived cannabinoids acts on these endogenous regulatory pathways.

In addition to pain modulation, cannabinoids also influence the inflammatory cascades typically associated with menstrual cramps and endometrial lesions. The activation of receptors can reduce the release of pro-inflammatory messengers in the tissue. Furthermore, preclinical studies indicate that cannabinoids could influence the proliferation of endometrial cells, which is significant for the research of new therapeutic approaches. However, as human data remains limited, these mechanisms are primarily considered as complementary options to conventional pain therapy.

• High density of CB1 and CB2 receptors throughout the female genital tract.
• Modulation of inflammatory mediators and pain signals in the pelvic area.
• Influence on the contraction of the smooth muscle of the uterus.
• Potential involvement of the endocannabinoid system in the regulation of endometrial growth.

Medical application and prescribing practice in Switzerland

In Switzerland, the legal situation for patients with chronic pelvic pain has been fundamentally simplified. Since August 2022, medical cannabis has been directly accessible via medical prescription, without the need to obtain a time-consuming exceptional permit from the Federal Office of Public Health (BAG). Gynecologists and general practitioners can prescribe corresponding formulations directly, provided there is a medical indication such as therapy-resistant chronic pain. This change facilitates access to standardized, quality-tested preparations which, unlike unregulated products, allow for precise dosing.

For legal use, various dosage forms such as oily solutions, capsules, or flowers for inhalation are available. While CBD products with a THC content of less than one percent are freely available, THC-dominant or balanced preparations are subject to the Narcotics Act (BetmG). Patients must note that the costs of these therapies are generally only covered by health insurance companies upon request and on a case-by-case basis. Close consultation with the treating physician is therefore essential for cost clarification.

• Direct medical prescription requirement for THC-containing medicinal products since August 2022.
• Approval of standardized formulations by Swissmedic to ensure patient safety.
• Cost coverage by the obligatory health insurance only after case-by-case review.
• Unrestricted purchase of CBD preparations with a total THC content of less than one percent.

Safety aspects, side effects and road traffic

The use of cannabinoids requires a careful weighing of benefits and risks, especially with long-term use to relieve chronic symptoms. Although CBD is generally considered well-tolerated, side effects such as fatigue, gastrointestinal complaints or interactions with other medications can occur. Since many endometriosis patients take hormonal preparations or painkillers, potential interactions in liver metabolism must be taken into account. Specialist medical supervision ensures that undesirable interactions are minimized and dosages are individually tailored to the patient.

An often underestimated aspect of everyday life is the legal situation in Swiss road traffic. A strict limit of 1.5 micrograms per liter of blood applies to THC, which in practice corresponds to a zero-tolerance rule. Since THC and its metabolites can be detected in the body even days after consumption, patients risk having their driver's license revoked due to unfitness to drive during a traffic check. This also applies to medically prescribed cannabis, which is why driving-related activities during THC therapy must be discussed in detail with their doctors.

• Possible side effects such as drowsiness, dry mouth and changes in blood pressure.
• Interactions with hormonal contraceptives and common painkillers via the cytochrome P450 system.
• Strict zero-tolerance practice in Swiss road traffic with a limit of 1.5 micrograms per liter of blood.
• Recommendation for regular monitoring of liver values during high-dose, long-term use.

FAQ